Positive phase 3 dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in rad 2021 late-breaking session

Tarrytown, n.y. and paris, dec. 13, 2021 /prnewswire/ -- dupixent significantly improved skin clearance and reduced overall disease severity and itch in pivotal trial that met all primary and secondary endpoints global regulatory filings planned in the coming months, starting with the u.s. by the end of 2021 regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced detailed positive phase 3 results that showed adding dupixent® (dupilumab) to standard-of-care topical corticosteroids (tcs) significantly improved skin clearance and reduced overall disease severity and itch in infants and children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis.
REGN Ratings Summary
REGN Quant Ranking